Are the ingredients of the Japanese version of Anamorelin the same as the domestic drug?

Anamorelin (Anamorelin) is a new type of ghrelin receptor agonist. The version available in the international market is mainly the original drug developed and produced by Otsuka Pharmaceutical Company of Japan. The drug is marketed as Anamorelin Hydrochloride and is mainly used for the treatment of cancer-related cachexia. It has been approved in Japan for nutritional support treatment of patients with non-small cell lung cancer. So far, there is no domestically produced version of Anamorelin that has been approved for marketing in mainland China. That is, no domestic pharmaceutical company has yet developed a generic drug or substitute with the same ingredients and approved by the Food and Drug Administration. Therefore, the anamulin used by patients on the market is basically derived from the original Japanese version.

In terms of ingredients, Japan’s original version of Anamorelin uses a ghrelin receptor agonist molecule with clear pharmacological activity and high selectivity, which can activate the hunger signaling pathway through specific binding sites. Because it is a patented drug, even if domestic R&D companies try to imitate it, they will not be able to enter the clinical market without passing the consistency evaluation or obtaining approval from the National Medical Products Administration. This means that there is currently no version in China that is identical in ingredients to the original drug and is sold in compliance with regulations.

In actual clinical use, doctors often recommend patients to obtain the original Japanese version of the drug through formal channels and conduct treatment based on its pharmacokinetic properties and standard dosage. At the same time, since Anamorelin treats wasting syndrome that is closely related to cancer, the effects and side effects need to be strictly monitored at every stage of medication. Non-standard versions may cause irreversible treatment delays.

In general, there is currently no truly domestically produced anamulin available on the market in mainland China, and there are obvious gaps with the original Japanese drug in terms of ingredients, quality control and clinical verification.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC4677053/